FDA panel to weigh Myozyme expansion

The FDA questions whether a study submitted by Genzyme is strong enough to merit expanded approval of a drug to treat a rare illness known as Pompe disease; the drug, Myozyme, is up for advisory committee discussion tomorrow. Report

Suggested Articles

Mobile has become universal, accessible, and multi-generational. It’s time for life science brands to revolutionize how they’re telling their story.

Former Retrophin CEO was hoping for a SCOTUS hail mary to escape his seven-year fraud sentences Turns out the court was interest in hearing his plea.

A new investigation shines light on how Purdue pushed back on negative coverage of opioids, placed opioid-friendly experts in think tanks and more.